Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
NCT ID: NCT01266707
Last Updated: 2010-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
9 participants
INTERVENTIONAL
2007-03-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vaccine
VEGRF1, VEGFR2
antiangiogenic paptide vaccine
for drugs include administration time frame
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
antiangiogenic paptide vaccine
for drugs include administration time frame
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease by CT scan
* ECOG performance status 0-2
* Life expectancy \> 3 months
* Laboratory values as follows: 2,000/mm3 \< WBC \<15,000/mm3, Platelet counts \> 75,000/mm3, Total Bilirubin \< 1.5 mg/dl, Asparate transaminase \< 150IU/L, Alanine transaminase \< 150 IU/L, Creatinine \< 3.0mg/dl
* HLA-A\*2402
* Able and willing to give valid written informed consent
Exclusion Criteria
* Brest-feeder
* Active or uncontrolled infection
* Steroids or immunosuppressing agent dependent status
* Active or uncontrolled other malignancy
* Serious or uncured wound
* Decision of unsuitableness by principal investigator or physician-in charge
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Human Genome Center, Institute of Medical Science, University of Tokyo
OTHER
Fukushima Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fukushima Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mitsukazu Gotoh, PhD & MD
Role: STUDY_CHAIR
Fukushima Medical University, Department of Regeneration Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fukushima Medical University Hospital
Fukushima, Fukushima, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Akira Kenjo, MD
Role: primary
Takashi Kimura, PhD & MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. doi: 10.1038/nm1202-794. Epub 2002 Nov 4.
Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9. doi: 10.1158/1078-0432.CCR-06-0750.
Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. doi: 10.1158/0008-5472.CAN-04-3759.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
560
Identifier Type: -
Identifier Source: org_study_id